Table 5 Rates of SR and cumulative... | American Society of Hematology

Table 5

Rates of SR and cumulative incidence of CR by the initial stage of GI GVHD

Marker	Stage 1			Stage 2			Stage 3
Marker	N	CR, %	SR, %	N	CR, %	SR, %	N	CR, %	SR, %
All patients	23	87	30	14	79	57	14	57	86
Calprotectin, μg/g stool
< 100	20	85	25	8	88	25	7	86	71
≥ 100	3	100	67	6	67	100	7	29	100
P		.25	.21		.27	.021		.022	.46
α1-AT, mg/g dw
< 1.5	15	87	27	4	100	0	2	100	50
≥ 1.5	8	88	38	10	70	80	12	50	92
P		.25	.66		.001	.015		.23	.27
No. of positive markers
0	14	86	21	4	100	0	2	100	50
1	7	86	43	4	75	50	5	80	80
2	2	100	50	6	67	100	7	29	100
P		.49	.40		.005	.004		.068	.23

Marker	Stage 1			Stage 2			Stage 3
Marker	N	CR, %	SR, %	N	CR, %	SR, %	N	CR, %	SR, %
All patients	23	87	30	14	79	57	14	57	86
Calprotectin, μg/g stool
< 100	20	85	25	8	88	25	7	86	71
≥ 100	3	100	67	6	67	100	7	29	100
P		.25	.21		.27	.021		.022	.46
α1-AT, mg/g dw
< 1.5	15	87	27	4	100	0	2	100	50
≥ 1.5	8	88	38	10	70	80	12	50	92
P		.25	.66		.001	.015		.23	.27
No. of positive markers
0	14	86	21	4	100	0	2	100	50
1	7	86	43	4	75	50	5	80	80
2	2	100	50	6	67	100	7	29	100
P		.49	.40		.005	.004		.068	.23

Rates of SR are compared with Fisher exact tests and cumulative incidences of CR by Gray tests.

SR indicates stereo resistant; CR, complete response; GI, gastrointestinal; AT, antitrypsin; and dw, dry weight.